TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01618422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Directly Observed Therapy (DOTS) plus
Description: The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Directly Observed Therapy (DOTS)
Description: The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
Study: NCT02186561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device
Study: NCT03983226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Tumor debulking surgery (surgery in recurrent ovarian disease)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...
Description: Salvage chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...
Description: Salvage chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib maintenance therapy
Study: NCT02879370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Inspection and management of low ColoRectal Anastomosis
Description: Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
Study: NCT02312115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Diuretic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00169910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AUC monitored withdrawal of MMF or CNI
Description: AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AUC monitored withdrawal of MMF or CNI
Description: AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
Study: NCT03758872

Intervention type: DIAGNOSTIC_TEST
Intervention: cuff assisted colonoscopy(with cuff use of endocuff vision second generation)
Description: this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
Study: NCT01037972

Intervention type: BEHAVIORAL
Intervention: Conventional physiotherapy
Description: 3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.

Intervention type: BEHAVIORAL
Intervention: Whole body vibration
Description: 3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
Study: NCT00909818

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard fractionated radiotherapy
Description: standard fractionated radiotherapy 50 Gy/25 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: hypofractionated radiotherapy 40 Gy/15 fractions
Study: NCT00656084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone
Description: Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan.
Study: NCT03906175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia
Description: Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
Study: NCT03014921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iron injection
Description: Injection of a 250mL saline solution added with 500mg of iron (Ferinject)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution injection
Description: Injection of a 250mL saline solution
Study: NCT00249795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: oral administration (tablets) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration (tablets) once daily
Study: NCT03305406

Intervention type: OTHER
Intervention: Interviews
Description: Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
Study: NCT03536650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMR
Description: Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita
Study: NCT02455778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Study: NCT01753466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydration
Study: NCT04317209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410
Description: administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered intravenously
Study: NCT03734406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videoclips
Description: The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
Study: NCT03131674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical physical therapy
Description: Patients receive a multimodal cervical physical therapy treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical physical therapy
Description: Patients receive a multimodal cervical physical therapy treatment
Study: NCT04243434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CHOP
Description: CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CHOP
Description: CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: R-CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: R-CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
Study: NCT02455778

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02053558

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systemic lidocaine
Description: Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
Study: NCT04751084

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buscopan 20 milligrams/ML Injectable Solution
Description: cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buscopan 20 milligrams/ML Injectable Solution
Description: cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
Study: NCT02027675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat poor micronutrient meal
Description: The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat poor micronutrient meal
Description: The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean meal
Description: The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean meal
Description: The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
Study: NCT03986736

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis - upon admission
Description: Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis - 24 hours after injury
Description: Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
Study: NCT01935466

Intervention type: DRUG
Intervention: Pioglitazone
Description: Ever users of Pioglitazone
Study: NCT02676362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival crevicular fluid collection with filter paper
Description: Gingival Crevicular Fluid Dynamics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival crevicular fluid collection with filter paper
Description: Gingival Crevicular Fluid Dynamics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival crevicular fluid collection with filter paper
Description: Gingival Crevicular Fluid Dynamics
Study: NCT00698880

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right hepatic vein embolization
Description: Embolization of the right hepatic vein
Study: NCT00761865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Cast Stirrup Brace & High Tide Fracture Boot
Description: Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
Study: NCT02053558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP BLOCK with ropivacaine
Description: TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
Study: NCT03723499

Intervention type: OTHER
Intervention: Medical data collection
Description: Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
Study: NCT03859141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (contains B/Victoria strain)
Description: One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (contains B/Yamagata strain)
Description: One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
Study: NCT04414761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH Antagonist
Description: GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Study: NCT00259272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
Study: NCT02232594

Intervention type: DRUG
Intervention: Berodual®
Study: NCT01641965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home pressure ventilator model Vivo 40 (BREAS Medical AB)
Description: Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \< 45 mmHg and improve symptoms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home pressure ventilator model Vivo 40 (BREAS Medical AB)
Description: Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \< 45 mmHg and improve symptoms.
Study: NCT02379611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fNIRS (Functional Near Infrared Spectroscopy)
Description: fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fNIRS (Functional Near Infrared Spectroscopy)
Description: fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
Study: NCT04628273

Intervention type: PROCEDURE
Intervention: encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy

Intervention type: PROCEDURE
Intervention: encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy
Study: NCT05148169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRIs
Description: One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SSRI plus Sulforaphane
Description: One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening.
Study: NCT04806529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)
Description: Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
Study: NCT02326389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
Study: NCT01227304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCCO-parameter-guided volume challenge
Description: Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
Study: NCT03771443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental gluten free toothpaste
Description: we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
Study: NCT03162029

Intervention type: OTHER
Intervention: CBCT imaging
Description: CBCT imaging of participants, then take measurement by radiomorphometric indices

Intervention type: OTHER
Intervention: CBCT imaging
Description: CBCT imaging of participants, then take measurement by radiomorphometric indices
Study: NCT03274180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing consultation
Description: travel preventive consultation was performed by nurse